Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease
VT-5006 is a first-in-class small molecule designed to precisely engage a validated peripheral target to delay onset and slow progression of Parkinson’s disease
WOBURN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) — Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has initiated a Phase 1 study of its lead candidate, VT-5006, a first-in-class, gut-selective small molecule for the treatment of Parkinson’s disease (PD).
VT-5006 is a novel, oral therapeutic developed by Vertero that acts on CsgA, a microbial amyloid present in the GI wall that drives aggregation of alpha-synuclein (⍺Syn) and inflammation, which propagates to the brain and provokes PD progression. By targeting CsgA, VT-5006 aims to reduce the load of aggregation and dampen inflammation — potentially both alleviating symptoms and slowing disease progression to preserve functionality for affected individuals.
“We have reached an important milestone for Vertero as we transition into clinical development for VT-5006. This program reflects our strategy to change the way we approach neurodegenerative diseases by targeting causative triggers in peripheral systems that fuel these diseases,” said Becca Senter, Ph.D., Chief Scientific Officer.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?